Chongqing Daxin Pharmaceutical Co., Ltd. (formerly Chongqing No.5 Pharmaceutical Factory,) was founded in 1941. It is located in Shuitu Industrial Area, Liangjiang New District, Chongqing, adjacent to Chongqing International Convention and Exhibition Center and around 20 kilometers away from Chongqing Jiangbei International Airport, boasting an advantageous geographical location and convenient transportation. The company launched the construction of its new plant in 2010, covering a total area of approximately 74.13 acres with a building area of 167,449.72 ㎡, and was officially completed and put into operation in 2013.
With more than 80 years development, the company has grown into a National Torch Program Key High-Tech Enterprise, a National Key Enterprise in the Chemical Pharmaceutical Industry, and one of the Top 100 Enterprises in China's Pharmaceutical Industry. It has also been recognized as a Chongqing High-Tech Enterprise, a Chongqing Technological Innovation Demonstration Enterprise, and a Chongqing Key Supported Enterprise for Export Best-Selling Brands. Over 80 years of strenuous efforts have made the company a comprehensive export-oriented biopharmaceutical enterprise led by biotechnology and specialized in characteristic APIs and pharmaceutical intermediates. It is also the largest microbial fermentation enterprise in Southwest China.
The company has got strong manufacturing capabilities, with 13 modern production workshops and a total fermentation volume of over 5,600m3. It produces more than 60 products, covering APIs and pharmaceutical intermediates in multiple categories such as nutritional drugs, lipid regulators, antibiotics (predominantly super antibiotics), immunomodulators, anti-tumor agents, and metabolic regulators, as well as raw materials for animal health, food and health products. In recent years, the company has actively expanded into CDMO (Contract Development and Manufacturing Organization) services and has carried out customized process development and production for dozens of products with more than 20 enterprises.
The company has established a complete quality assurance system and has successively obtained approval from cGMP, FDA and EDQM, enabling it to provide high-quality products that meet CP, USP, EP and customized standards. Adhering to the concept of sustainable development, the company has built a mature and comprehensive EHS management system, strengthened full-process risk management, and strictly abided by compliance bottom lines. The company continues to enhance the construction of a complete technical system covering new product R&D, industrialization transformation and intellectual property protection, with more than 60 authorized invention patents. In the future, Relying on the platform advantages of the Group Research Institute and the company’s Technical Center, the company will accelerate the launch of new products, continuously enrich product pipeline and optimize product structure, striving to build a bio-manufacturing benchmark enterprise with characteristic APIs as the core and international competitiveness.